The ongoing competition between small-cap medical companies Ekso Bionics and LENSAR highlights distinct differences in institutional ownership, profitability, and analyst ratings. Both firms operate in the healthcare sector but target different markets with their innovative technologies. This article examines their performance across various financial metrics to determine which company stands out.
Earnings and Valuation Insights
A comparison of the financial health of Ekso Bionics and LENSAR reveals key differences. Ekso Bionics has a market capitalization that reflects its growth potential, while LENSAR’s financial metrics indicate a stronger foothold in its niche.
As of the latest reports, Ekso Bionics has a consensus target price of $10.50, suggesting a potential upside of 91.96%. In contrast, LENSAR’s target price stands at $15.00, with a more modest potential upside of 24.90%. Analysts view these figures as indicators of future performance, with Ekso Bionics currently positioned more favorably.
Ownership Structures and Analyst Perspectives
Institutional ownership serves as an important indicator of confidence among large investors. Currently, 6.4% of Ekso Bionics shares are held by institutional investors, while 40.2% of LENSAR shares fall under this category. Additionally, insider ownership is significantly higher at LENSAR, with 66.0% of shares owned by company insiders compared to just 6.0% for Ekso Bionics.
Such ownership dynamics suggest that LENSAR may enjoy stronger support from its management, potentially translating into strategic advantages in future endeavors.
Profitability and Risk Assessment
Profitability metrics indicate that both companies are working toward sustainable growth. The net margins and return on equity for each firm demonstrate varying levels of efficiency and effectiveness in generating profits.
Risk is another critical factor for investors. Ekso Bionics has a beta of 0.82, indicating that its share price is 18% less volatile than the S&P 500. Conversely, LENSAR boasts a beta of 0.66, marking it as 34% less volatile, which may appeal to risk-averse investors.
Company Profiles
Ekso Bionics Holdings, Inc., founded in 2005 and based in San Rafael, California, specializes in designing and developing exoskeleton products for medical and industrial applications. Its two segments, EksoHealth and EksoWorks, focus on different markets. The EksoHealth segment creates devices to assist with rehabilitation for conditions such as spinal cord injuries, while EksoWorks produces exoskeletons aimed at enhancing productivity in physically demanding jobs.
On the other hand, LENSAR, Inc., established in 2004 and headquartered in Orlando, Florida, develops advanced femtosecond laser systems for cataract surgery. The LENSAR Laser System combines innovative imaging and procedure planning technologies to improve surgical outcomes. Their ALLY Adaptive Cataract Treatment System further enhances the capabilities of this technology, streamlining the surgical process for ophthalmologists.
In summary, while both Ekso Bionics and LENSAR contribute significantly to the medical technology landscape, Ekso Bionics currently outperforms LENSAR in several key areas, including potential upside and analyst ratings. As they continue to innovate and adapt to market demands, investors will be closely watching their progress and strategies in the coming years.
